Type 2 diabetes drug can significantly reduce hospitalization for heart failure and lead to death

Recently, a new study published in international academic journals NEJM first to suggest a type 2 diabetes drug can significantly reduce hospitalizations for heart failure and lead to death.
 The findings come from a known EMPA-REG OURCOME of large clinical trials, from Yale University, Dr. Silvio E. Inzucchi held in Orlando in 2015 the American Heart Association scientific meetings about the progress of this research.
 Many patients with type 2 diabetes are also at the same time the presence of heart failure, the heart they can not effectively pump blood into the circulation system. The current treatment of treatment of heart failure is very limited, but some studies have found no previous treatment of type 2 diabetes in heart failure have a therapeutic effect. But an increase in the blood glucose is discharged through urine by new therapeutic drugs to achieve glycemic control (SGLT2 inhibitors) has not been studied.
 In this EMPA-REG experiments, researchers will have type 2 diabetes in patients with heart disease risk while randomized, to some patients taking a new antidiabetic drugs --empagliflozin (10mg or 25mg dose) each day, as well as Some patients taking placebo. Drug and placebo are administered in addition to standard treatment.
 To the end of the experiment, the researchers found that compared with patients taking placebo, patients taking the drug blood sugar and blood pressure declined, while weight also declined. They also found that patients taking the drug died of heart disease, the proportion declined significantly; the proportion of hospitalizations due to heart failure also appears significantly decreased; the proportion of deaths from any cause was also significantly decreased.
 In addition, Inzucchi and colleagues there and the absence of heart failure, heart failure patients with type 2 diabetes start of the test carried out further analysis showed that the ratio of these two groups of patients had decrease in hospitalizations are similar, So they come to a conclusion, empagliflozin already suffering not only to prevent further deterioration in patients with heart failure, but also not suffering from heart failure can help prevent heart failure in patients with diabetes.
 August 2014 Boehringer Ingelheim - Lilly Diabetes Federation announced, diabetes DRUG Jardiance (empagliflozin) approved by the FDA, combined with diet and exercise for adult patients with type 2 diabetes therapy to improve blood sugar control.